Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers.

Journal of cancer research and clinical oncology - 1 Nov 2022

Kim Sang-A, Park Hyejoo, Kim Kui-Jin, Kim Ji-Won, Sung Ji Hea, Nam Milang, Lee Ju Hyun, Jung Eun Hee, Suh Koung Jin, Lee Ji Yun, Kim Se Hyun, Lee Jeong-Ok, Kim Jin Won, Kim Yu Jung, Kim Jee Hyun, Bang Soo-Mee, Lee Jong Seok, Lee Keun-Wook

Abstract excerpt

PURPOSE: Recent evidence has highlighted the role of hepatocyte growth factor (HGF) as a putative biomarker to predict EGFR inhibitor resistance. This study investigated the impact of plasma HGF levels on EGFR inhibition and the counter effect of MET inhibition in KRAS, NRAS, and BRAF (RAS/RAF) wild-type colorectal cancers (CRCs). METHODS: Plasma HGF levels were analyzed with clinical outcomes of patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caco-2 Cells

Share to Cetuximab

Share to GTP Phosphohydrolases

Share to Hepatocyte Growth Factor

Share to Imidazoles

Share to Triazines

Source

Identifiers

PMID: 34853888
DOI: 10.1007/s00432-021-03872-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers.PMID 34853888Read ↗

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.Semantic proximity Read ↗

The current state of molecularly targeted drugs targeting HGF/Met.Semantic proximity Read ↗

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?Semantic proximity Read ↗

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.Semantic proximity Read ↗

Role of cMET in the Development and Progression of Colorectal CancerSemantic proximity Read ↗

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.Semantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

Targeting the hepatocyte growth factor/Met pathway in cancer.Semantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.Semantic proximity Read ↗

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.Semantic proximity Read ↗

Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.